Understanding Meningococcal B Vaccine Safety
Myth: The Meningococcal B Vaccine is Unsafe
This assertion is incorrect. The meningococcal B vaccine is designed to protect individuals from the severe illness of meningitis.
Development and Licensing of the Vaccine
The vaccine was licensed in Europe in 2013 after undergoing extensive clinical trials to establish its safety and effectiveness. While some unexpected side effects, such as fever and skin reactions, were noted, these were carefully monitored.
Recent Safety Assessments
A recent study conducted in the United Kingdom further evaluated the safety of the meningococcal B vaccine. The findings were published in The Lancet Child & Adolescent Health.
Study Overview
Researchers administered approximately 1.29 million doses of the vaccine, which equates to around 3 million doses over a span of 20 months. The study primarily involved children aged 18 months and younger.
Results and Conclusions
The overall findings indicated that the vaccine is beneficial, with minimal safety concerns reported.
Additional Information
For more details on this study, click here.
Reference
Bryan P, Seabroke S, Wong J, et al. Safety of multicomponent meningococcal group B vaccine (4CMenB) in routine infant immunisation in the UK: A prospective surveillance study. Lancet Child Adolesc Health. 2018;2(6):395-403. doi:10.1016/S2352-4642(18)30103-2